BI Asset Management Fondsmaeglerselskab A S Boosts Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

BI Asset Management Fondsmaeglerselskab A S increased its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 45.1% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 427,207 shares of the biopharmaceutical company's stock after purchasing an additional 132,795 shares during the period. BI Asset Management Fondsmaeglerselskab A S owned approximately 0.34% of Halozyme Therapeutics worth $20,425,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its position in shares of Halozyme Therapeutics by 3.0% during the fourth quarter. Vanguard Group Inc. now owns 13,281,714 shares of the biopharmaceutical company's stock worth $634,999,000 after acquiring an additional 386,618 shares during the period. Dimensional Fund Advisors LP boosted its stake in shares of Halozyme Therapeutics by 2.5% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,933,560 shares of the biopharmaceutical company's stock valued at $92,446,000 after buying an additional 47,795 shares during the period. Charles Schwab Investment Management Inc. grew its position in shares of Halozyme Therapeutics by 0.6% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,783,177 shares of the biopharmaceutical company's stock worth $85,254,000 after buying an additional 9,780 shares in the last quarter. Norges Bank purchased a new stake in shares of Halozyme Therapeutics during the fourth quarter worth approximately $60,054,000. Finally, Arrowstreet Capital Limited Partnership lifted its stake in Halozyme Therapeutics by 141.3% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 992,887 shares of the biopharmaceutical company's stock worth $47,470,000 after acquiring an additional 581,475 shares during the last quarter. Institutional investors and hedge funds own 97.79% of the company's stock.

Insider Activity

In related news, Director Jeffrey William Henderson sold 5,000 shares of the company's stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $56.30, for a total value of $281,500.00. Following the sale, the director now owns 38,611 shares in the company, valued at $2,173,799.30. This represents a 11.46 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, SVP Michael J. Labarre sold 10,000 shares of Halozyme Therapeutics stock in a transaction on Tuesday, February 25th. The stock was sold at an average price of $58.05, for a total value of $580,500.00. Following the transaction, the senior vice president now directly owns 185,453 shares of the company's stock, valued at approximately $10,765,546.65. This represents a 5.12 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 22,200 shares of company stock valued at $1,286,568 in the last three months. 2.90% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

HALO has been the topic of a number of recent analyst reports. JPMorgan Chase & Co. increased their price objective on shares of Halozyme Therapeutics from $55.00 to $58.00 and gave the company a "neutral" rating in a research report on Monday. Benchmark reiterated a "buy" rating and issued a $75.00 price objective on shares of Halozyme Therapeutics in a report on Thursday, February 20th. Wells Fargo & Company decreased their target price on Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating for the company in a research note on Monday, January 13th. Piper Sandler raised their price objective on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a "neutral" rating in a report on Friday, January 10th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $72.00 target price on shares of Halozyme Therapeutics in a research report on Friday. Four analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $62.89.

Halozyme Therapeutics Stock Performance

Shares of NASDAQ:HALO traded up $1.30 during trading on Friday, reaching $60.55. The company had a trading volume of 395,957 shares, compared to its average volume of 1,445,281. Halozyme Therapeutics, Inc. has a fifty-two week low of $37.97 and a fifty-two week high of $66.00. The company has a debt-to-equity ratio of 4.14, a current ratio of 7.80 and a quick ratio of 9.15. The stock's fifty day moving average price is $60.43 and its 200 day moving average price is $55.01. The firm has a market capitalization of $7.48 billion, a price-to-earnings ratio of 17.66, a price-to-earnings-growth ratio of 0.42 and a beta of 1.32.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last announced its quarterly earnings data on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.17 by $0.02. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. The company had revenue of $298.01 million for the quarter, compared to analysts' expectations of $285.74 million. As a group, equities research analysts predict that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.